TARGETING OF IMMUNOLIPOSOMAL VINCRISTINE TO HEMATOLOGICAL MALIGNANCIES

摘要

We have developed long circulating immunoliposomal formulations of vincristine using whole murine monoclonal antibody anti-CD-19 or anti-CD19-Fab' as targeting moieties. The immunoliposomes had higher binding/uptake and higher cytotoxicities than non-targeted liposomes in a CD19~+ human B-cell lymphoma cell line (Namalwa). The circulation half-life of Fab'-coupled liposomes was similar to non-targeted liposomes and significantly shorter than for liposomes coupled with whole antibody.